How Rare Is CRPS? Prevalence, Risk, and Recovery

Complex regional pain syndrome affects a small fraction of the general population, but among people who have recently had a fracture or surgery, it is not as uncommon as many assume. The largest U.S. inpatient study found that about 0.07% of hospitalized patients carried a CRPS diagnosis, while a claims-database analysis put the figure closer to 1.2% of insured patients with pain-related visits. Those numbers sit far apart, partly because CRPS is notoriously hard to diagnose and partly because the populations being measured differ. The condition sits in an awkward space: rare enough that many doctors will see only a handful of cases in a career, yet common enough that tens of thousands of people are living with it at any given time.

Prevalence and Incidence by the Numbers

Pinning down how many people have CRPS depends heavily on which database you query and how strictly the diagnosis is defined. A retrospective look at more than 33 million U.S. inpatient records from 2007 to 2011 identified about 22,500 patients discharged with a CRPS diagnosis, or roughly 0.07% of the total. A separate analysis of a commercial insurance database covering about 6.6 million patients found a higher overall prevalence of 1.2%, likely because that dataset captured outpatient visits and chronic pain claims rather than just hospital stays.¹ In other words, the “true” prevalence depends on whether you are counting only people sick enough to be hospitalized or also those managing the condition in clinics and pain centers.

Incidence figures from population-based studies outside the United States give additional perspective. A Dutch study reported that women were affected at least three times more often than men, with the highest incidence occurring among women aged 61 to 70.² A Korean electronic health data study found that incidence peaked even later, in the 70s age group, at about 66 per 100,000 person-years, though the sheer number of patients was highest among people in their 50s. Women had higher rates in both the type I and type II categories.³ The consistent finding across countries is that CRPS is more common in middle-aged and older women, though it can strike anyone.

Who Gets CRPS and Why

The typical patient is a woman over 50 who has recently had a fracture, surgery, or other limb trauma. The large U.S. inpatient study found that being female, white, having a higher household income, and having comorbidities like depression, drug use disorders, or chronic headache were all associated with a CRPS diagnosis. Interestingly, conditions like obesity, diabetes, and hypothyroidism were linked to lower rates.¹ A single-center European study found a similar demographic profile: about 73% of patients were women, with an average age near 61 for women and 52 for men.⁴

About 90% of CRPS cases are classified as type I, meaning there is no confirmed nerve injury. The remaining roughly 10% are type II, where a specific nerve lesion can be identified.⁵ Both types can produce the same devastating symptoms: burning pain, swelling, color changes, temperature differences between limbs, and loss of function. The distinction matters mainly for classification and, in some cases, for guiding treatment decisions.

Early research into genetic susceptibility has turned up a handful of gene variants that appear more frequently in people with CRPS type I than in the general population. A discovery cohort identified variants in genes related to ion channels and cellular signaling, though the sample was small and the findings are still considered preliminary.⁶ Having a family member with CRPS does not guarantee you will develop it, but the genetics work suggests that some people’s nervous and immune systems may be wired to overreact to trauma in ways that set the stage for the syndrome.

The Role of Psychological Factors

One of the more persistent myths about CRPS is that it is primarily a psychological condition, or that people who are anxious or depressed are simply more likely to develop it. The evidence is more complicated than that. A systematic review of risk factors for CRPS type I found that psychological factors carried weak weight as predictors. Catastrophizing, depression, and preoperative psychological distress were not reliably predictive of who would go on to develop the condition.⁷

That said, a large database study of over 163,000 ankle fracture patients found that the roughly 6% who went on to develop CRPS had significantly higher odds of having a pre-existing psychological disorder, with an odds ratio around 5.4. The conditions most strongly associated were delirium, bipolar disorder, and anxiety disorder.⁸ So while having anxiety or bipolar disorder does appear to increase risk after a fracture, the everyday stress and worry that most patients experience before surgery does not seem to be a meaningful trigger. The distinction matters because patients with CRPS sometimes feel dismissed, as if they are being told the pain is “all in their head.” The emerging picture is that CRPS is driven by immune and nervous system dysfunction, and certain psychiatric conditions may reflect overlapping neurobiology rather than a causal chain from mood to pain.

What Is Actually Happening in the Body

CRPS involves a cascade of runaway inflammation and nervous system changes that, in simple terms, keep the alarm bells ringing long after the original injury has healed. In the acute phase, the affected limb floods with inflammatory molecules, and pain signals get amplified at the spinal cord and brain level. Researchers have found elevated levels of multiple inflammatory proteins in the skin and muscle of the affected limb, and more recently, they have discovered that the immune system itself appears to turn against the body.⁹

One of the more striking findings in recent years is that antibodies from CRPS patients can actually transfer pain-like symptoms to mice. When researchers injected purified antibodies from people with longstanding CRPS into mice that had undergone a small skin incision, those mice developed prolonged swelling and heightened pain sensitivity compared with mice that received antibodies from healthy donors. The effect was driven in part by activation of immune cells in the spinal cord, and blocking a specific inflammatory pathway with a drug called anakinra prevented or reversed the changes.¹⁰ Autoantibodies targeting receptors on autonomic neurons have been detected in about 70% of CRPS patients, reinforcing the idea that autoimmunity plays a major role.¹¹

At the brain level, CRPS reshapes how the nervous system processes touch and pain. Functional brain imaging has shown that stimulating the affected limb activates a broader and more intense cortical network than the same stimulus applied to the unaffected side, involving sensory, emotional, and frontal brain regions.¹² Patients with widespread pain beyond the originally affected limb show even greater signs of this central sensitization, including disturbed body perception.¹³ This is why CRPS can feel so bewildering to patients: the pain is very real, rooted in measurable changes to both the immune system and the brain.

Warm and Cold Subtypes

Not all CRPS looks the same. A large clinical study identified two distinct clusters: a “warm” subtype characterized by a red, swollen, and sweaty limb, and a “cold” subtype with a blue, cool, and less puffy limb. Pain intensity was similar in both groups, but the timeline differed substantially. Warm CRPS patients had a median pain duration of about five months, while cold CRPS patients had a median of 20 months. The inflammatory markers in warm CRPS diminished over the first year, whereas in cold CRPS they stayed flat.¹⁴

These subtypes are not just academic categories. A follow-up study found that patients initially diagnosed with the cold subtype still showed greater signs of central sensitization and worse pain outcomes roughly eight years later.¹⁵ In practical terms, if your limb is warm and swollen early on, that may actually be a better prognostic sign than a cold, blue presentation, because the inflammatory process driving warm CRPS tends to fade. The cold subtype, by contrast, seems to reflect deeper nervous system changes that are harder to reverse.

Recovery Prospects at One Year and Beyond

The honest answer about CRPS recovery is that it improves for most people but fully resolves for very few within the first year. A prospective study tracking patients from onset found that almost all individual signs and symptoms improved over 12 months, with the biggest gains in the first six months. But at the one-year mark, roughly two-thirds of patients still met at least one set of diagnostic criteria for CRPS, and only about 5% were completely symptom-free.¹⁶ A systematic review covering studies that followed patients for 12 months or longer echoed this: symptoms improve for many people to the point where they no longer technically qualify for a CRPS diagnosis, but almost no one reports zero residual symptoms.¹⁷

Longer-term data paint a mixed picture depending on treatment. A telephone survey with up to five years of follow-up found that 71% of CRPS patients had severe functional impairment, and only 15% reported good outcomes.¹⁸ On the other hand, a study of patients treated early with the bisphosphonate neridronate found that about 94% no longer met diagnostic criteria for CRPS at follow-up, though roughly 22% still had some functional limitation. Crucially, the biggest predictor of residual disability in that group was delay between disease onset and treatment.¹⁹ The takeaway is clear: early, aggressive treatment appears to make a meaningful difference.

What Helps Recovery

There is no single treatment that works for everyone, but the evidence supports a few key strategies. Graded motor imagery, a rehabilitation technique where patients perform mental exercises involving their affected limb before gradually progressing to actual movement, has shown consistent results. A randomized controlled trial found it reduced pain by about 25 points on a neuropathic pain scale, with a number needed to treat of approximately two, meaning for every two patients treated, one achieved at least a 50% pain reduction.²⁰ Brain imaging studies have shown that this approach actually changes cortical activity, normalizing the overactive sensory maps that develop with CRPS.²¹

Mirror therapy, a related technique where a mirror creates the visual illusion of normal movement in the affected limb, has also shown meaningful pain reduction and functional improvement, particularly in CRPS that develops after stroke.²² These approaches work in part by retraining the brain’s distorted representation of the affected limb.

For people who do not respond to physical and occupational therapy approaches, more intensive interventions exist. Ketamine infusions have been used in treatment-resistant cases, and some literature suggests that roughly half of patients experience long-term pain relief from a single infusion, though systematic reviews have flagged the evidence as generally low quality.²³ Spinal cord stimulation is another option for refractory symptoms.²⁴ An economic analysis of spinal cord stimulation combined with physical therapy found a lifetime cost saving of about $61,000 compared with physical therapy alone, largely because it reduced other healthcare utilization and disability costs.²⁵

Can CRPS Be Prevented?

One of the more encouraging findings in CRPS research involves something cheap and widely available: vitamin C. Two separate meta-analyses have found that taking at least 500 mg of vitamin C daily, starting immediately after a limb fracture or surgery and continuing for about 45 to 50 days, significantly reduced the odds of developing CRPS. The earlier meta-analysis estimated a relative risk of 0.22, meaning roughly a 78% reduction in CRPS incidence with vitamin C compared with placebo.²⁶ A more recent meta-analysis confirmed the direction of the effect, finding an odds ratio of 0.33 in favor of vitamin C, though it noted no significant differences in complications, functional outcomes, or pain scores between groups.²⁷

This means vitamin C appears to lower the chance of CRPS developing in the first place, but if it does develop, vitamin C supplementation does not seem to make the symptoms less severe. Despite the favorable data, vitamin C prophylaxis is still not universally adopted by orthopedic surgeons, partly because some clinicians remain skeptical of the effect size and partly because awareness of CRPS prevention strategies is low. Given the minimal risk and cost, it is worth discussing with your surgical team if you are facing limb surgery or recovering from a fracture.

CRPS in Children and Adolescents

CRPS can also affect children, though the demographics look different from the adult population. Pediatric cases skew heavily toward adolescent girls, and the lower limbs are more commonly involved than in adults. The condition appears to carry a more favorable prognosis in younger patients, with higher rates of full recovery compared with adults.²⁸ That said, “favorable prognosis” does not mean quick or painless: pediatric CRPS can still be severely debilitating during active disease, and some children experience relapses. Treatment typically emphasizes intensive physical therapy and psychological support, with a stronger focus on functional rehabilitation than on medications.

The Economic Weight of CRPS

Beyond the personal burden, CRPS carries outsized financial costs. A Swiss study tracking accident insurance claims from 2008 to 2015 found that a single CRPS case accumulated average insurance costs of about $87,000 and treatment costs of about $23,000 over five years. Insurance costs were 19 times higher, and treatment costs 13 times higher, than the average for accidents without CRPS. Within the first two years after injury, CRPS patients missed an average of 330 days of work, compared with about 16 days for patients without the condition. Two-thirds of all CRPS cases developed long-term work incapacity lasting more than 90 days.²⁹ These numbers help explain why early diagnosis and treatment matter so much: every month of delay adds not only to suffering but to the economic toll on both patients and healthcare systems.

Why Diagnosis Remains Difficult

CRPS has no single blood test or imaging study that confirms it. Diagnosis relies on clinical criteria, and the criteria themselves have evolved over time. The Budapest Criteria, now widely used, improved diagnostic accuracy compared with older classification systems by requiring both reported symptoms and observed clinical signs across multiple categories: sensory, vasomotor, sudomotor (sweating), and motor/trophic changes.³⁰ The tradeoff is that stricter criteria mean fewer false positives but potentially more missed cases early on, when symptoms may not yet span all four categories.

Imaging can support but not replace clinical diagnosis. Three-phase bone scintigraphy, which tracks how blood flows through and is taken up by bone tissue, has shown usefulness in differentiating CRPS from non-CRPS limb pain, particularly in chronic cases.³¹ Infrared thermography, which measures skin temperature differences between limbs, has also demonstrated diagnostic value, with one study finding it was the only modality among three tests that reached statistical significance for diagnostic performance on its own.³² Neither test is definitive alone, but combining them with clinical criteria can increase diagnostic confidence. The real problem is often awareness: many patients report seeing multiple providers before anyone considers CRPS as a diagnosis, and that delay can shift the window on treatment and recovery.